KATHRYN E FALBERG Insider Trading Transactions
Get free email notifications about insider trading for KATHRYN E FALBERG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of KATHRYN E FALBERG. KATHRYN E FALBERG is Director in HUMAN GENOME SCIENCES INC ($HGSI) and Director in MEDIVATION, INC. ($MDVN) and Director in BIOMARIN PHARMACEUTICAL INC ($BMRN) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and Director in aTYR PHARMA INC ($LIFE) and in Tricida, Inc. ($TCDA) and Director in Tricida, Inc. ($TCDA) and Director in Aimmune Therapeutics, Inc. ($AIMT) and Director in Axovant Sciences Ltd. ($AXON) and Director in Trade Desk, Inc. ($TTD) and Director in UroGen Pharma Ltd. ($URGN) and Director in Arcus Biosciences, Inc. ($RCUS) and Director in Nuvation Bio Inc. ($PANA).
Latest Insider Trading Transactions of KATHRYN E FALBERG
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AIMT, RCUS, LIFE, BMRN, GYHT, HGSI, MDVN, NUVB, AXON, TTD, TCDA, URGN
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 02 2021 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 28.35 | 20,000 | 566,996 | 102,106 | 82.1 K to 102.1 K (+24.36 %) |
Feb 12 2021 | PANA | Nuvation Bio Inc. | FALBERG KATHRYN E | Director | Option Exercise | A | 4.60 | 239,361 | 1,101,061 | 239,361 | |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Option Exercise | C | 0.00 | 20,000 | 0 | 0 | |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Option Exercise | M | 0.00 | 20,000 | 0 | 20,000 | |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Option Exercise | M | 18.03 | 20,000 | 360,600 | 10,303 | |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 822.00 | 629 | 517,038 | 2,641 | 3.3 K to 2.6 K (-19.24 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 820.00 | 13 | 10,660 | 3,270 | 3.3 K to 3.3 K (-0.40 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 819.06 | 825 | 675,725 | 3,283 | 4.1 K to 3.3 K (-20.08 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 818.15 | 4,139 | 3,386,323 | 4,108 | 8.2 K to 4.1 K (-50.19 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 815.00 | 1,891 | 1,541,165 | 8,247 | 10.1 K to 8.2 K (-18.65 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 814.00 | 10 | 8,140 | 10,138 | 10.1 K to 10.1 K (-0.10 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 813.04 | 891 | 724,419 | 10,148 | 11 K to 10.1 K (-8.07 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 811.68 | 200 | 162,336 | 11,039 | 11.2 K to 11 K (-1.78 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 811.00 | 5,670 | 4,598,370 | 11,239 | 16.9 K to 11.2 K (-33.53 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 810.19 | 2,852 | 2,310,662 | 16,909 | 19.8 K to 16.9 K (-14.43 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 809.03 | 1,853 | 1,499,133 | 19,761 | 21.6 K to 19.8 K (-8.57 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 807.84 | 795 | 642,233 | 21,614 | 22.4 K to 21.6 K (-3.55 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 806.63 | 232 | 187,138 | 22,409 | 22.6 K to 22.4 K (-1.02 %) |
Nov 23 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | C | 0.00 | 20,000 | 0 | 22,641 | 2.6 K to 22.6 K (+757.29 %) |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | D | 17.11 | 15,398 | 263,460 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | D | 19.90 | 11,432 | 227,497 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | D | 32.79 | 7,500 | 245,925 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | D | 18.26 | 17,500 | 319,550 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | D | 15.40 | 19,755 | 304,227 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Sell | D | 34.50 | 7,840 | 270,480 | 0 | 7.8 K to 0 (-100.00 %) |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Sell | U | 34.50 | 69,894 | 2,411,343 | 0 | 69.9 K to 0 (-100.00 %) |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Sell | U | 34.50 | 65,192 | 2,249,124 | 0 | 65.2 K to 0 (-100.00 %) |
Jun 15 2020 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Director | Option Exercise | A | 25.40 | 22,967 | 583,362 | 22,967 | |
Jun 15 2020 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 5,670 | 0 | 42,760 | 37.1 K to 42.8 K (+15.29 %) |
Jun 10 2020 | URGN | UroGen Pharma Ltd. | FALBERG KATHRYN E | Director | Option Exercise | A | 28.24 | 10,000 | 282,400 | 10,000 | |
Jun 08 2020 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Option Exercise | A | 30.05 | 14,000 | 420,700 | 14,000 | |
Jun 08 2020 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 3,000 | 0 | 83,504 | 80.5 K to 83.5 K (+3.73 %) |
May 29 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | A | 17.11 | 15,398 | 263,460 | 15,398 | |
May 29 2020 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 7,840 | 0 | 73,032 | 65.2 K to 73 K (+12.03 %) |
May 28 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 249.66 | 20 | 4,993 | 2,641 | 2.6 K to 2.6 K (+0.76 %) |
May 28 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 249.66 | 64 | 15,978 | 2,621 | 2.6 K to 2.6 K (+2.50 %) |
May 28 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 249.66 | 180 | 44,939 | 2,557 | 2.4 K to 2.6 K (+7.57 %) |
May 28 2020 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 901 | 0 | 2,377 | 1.5 K to 2.4 K (+61.04 %) |
Nov 13 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 206.95 | 19,500 | 4,035,566 | 20,000 | 39.5 K to 20 K (-49.37 %) |
Nov 13 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 207.08 | 10,286 | 2,130,019 | 1,476 | 11.8 K to 1.5 K (-87.45 %) |
Jun 14 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 8.52 | 12,935 | 110,152 | 82,106 | 69.2 K to 82.1 K (+18.70 %) |
Jun 13 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 8.49 | 10,000 | 84,928 | 69,171 | 59.2 K to 69.2 K (+16.90 %) |
Jun 13 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 7.90 | 10,000 | 79,000 | 59,171 | 49.2 K to 59.2 K (+20.34 %) |
Jun 11 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 8.25 | 10,000 | 82,500 | 49,171 | 39.2 K to 49.2 K (+25.53 %) |
Jun 11 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 7.99 | 22,065 | 176,297 | 39,171 | 17.1 K to 39.2 K (+128.99 %) |
Jun 10 2019 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Option Exercise | A | 7.99 | 35,000 | 279,650 | 35,000 | |
Jun 05 2019 | URGN | UroGen Pharma Ltd. | FALBERG KATHRYN E | Director | Option Exercise | A | 34.83 | 10,000 | 348,300 | 10,000 | |
Jun 04 2019 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Director | Option Exercise | A | 36.74 | 7,068 | 259,678 | 7,068 | |
Jun 04 2019 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 1,879 | 0 | 37,090 | 35.2 K to 37.1 K (+5.34 %) |
May 28 2019 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | A | 19.90 | 11,432 | 227,497 | 11,432 | |
May 28 2019 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 6,442 | 0 | 65,192 | 58.8 K to 65.2 K (+10.97 %) |
May 28 2019 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Gift | G | 0.00 | 69,894 | 0 | 69,894 | 0 to 69.9 K |
May 28 2019 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Gift | G | 0.00 | 69,894 | 0 | 58,750 | 128.6 K to 58.8 K (-54.33 %) |
May 02 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 207.03 | 48 | 9,937 | 11,762 | 11.7 K to 11.8 K (+0.41 %) |
May 02 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 207.03 | 77 | 15,941 | 11,714 | 11.6 K to 11.7 K (+0.66 %) |
May 02 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 207.03 | 48 | 9,937 | 11,637 | 11.6 K to 11.6 K (+0.41 %) |
May 02 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 207.03 | 217 | 44,926 | 11,589 | 11.4 K to 11.6 K (+1.91 %) |
May 02 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 1,086 | 0 | 11,372 | 10.3 K to 11.4 K (+10.56 %) |
Mar 13 2019 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 205.47 | 40,000 | 8,218,964 | 20,000 | 60 K to 20 K (-66.67 %) |
Nov 30 2018 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Sell | S | 134.84 | 20,000 | 2,696,692 | 60,000 | 80 K to 60 K (-25.00 %) |
Nov 30 2018 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Gift | G | 0.00 | 500 | 0 | 49,786 | 50.3 K to 49.8 K (-0.99 %) |
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Option Exercise | A | 19.00 | 13,147 | 249,793 | 13,147 | ||
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Option Exercise | A | 19.00 | 13,147 | 249,793 | 13,147 | ||
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Grant | A | 0.00 | 3,632 | 0 | 35,211 | 31.6 K to 35.2 K (+11.50 %) | |
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Grant | A | 0.00 | 3,632 | 0 | 35,211 | 31.6 K to 35.2 K (+11.50 %) | |
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Buy | P | 19.00 | 31,579 | 600,001 | 31,579 | 0 to 31.6 K | |
Jul 02 2018 | TCDA | Tricida, Inc. | FALBERG KATHRYN E | Buy | P | 19.00 | 31,579 | 600,001 | 31,579 | 0 to 31.6 K | |
May 24 2018 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | A | 32.79 | 7,500 | 245,925 | 7,500 | |
May 24 2018 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 3,750 | 0 | 128,644 | 124.9 K to 128.6 K (+3.00 %) |
May 07 2018 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 49.44 | 1,638 | 80,983 | 50,286 | 48.6 K to 50.3 K (+3.37 %) |
May 07 2018 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 4,045 | 0 | 48,648 | 44.6 K to 48.6 K (+9.07 %) |
Mar 19 2018 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Option Exercise | C | 0.00 | 17,106 | 0 | 0 | |
Mar 19 2018 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | P | 15.00 | 30,000 | 450,000 | 80,504 | 50.5 K to 80.5 K (+59.40 %) |
Mar 19 2018 | RCUS | Arcus Biosciences, ... | FALBERG KATHRYN E | Director | Buy | C | 0.00 | 17,106 | 0 | 17,106 | 0 to 17.1 K |
Feb 26 2018 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Buy | P | 32.00 | 30,000 | 960,000 | 124,894 | 94.9 K to 124.9 K (+31.61 %) |
Jul 24 2017 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 54.52 | 1,302 | 70,985 | 44,603 | 43.3 K to 44.6 K (+3.01 %) |
Jul 24 2017 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 3,301 | 0 | 43,301 | 40 K to 43.3 K (+8.25 %) |
Jun 16 2017 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | P | 48.06 | 20,000 | 961,154 | 80,000 | 60 K to 80 K (+33.33 %) |
May 30 2017 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | A | 18.26 | 17,500 | 319,550 | 17,500 | |
May 16 2017 | AXON | Axovant Sciences L ... | FALBERG KATHRYN E | Director | Option Exercise | A | 21.90 | 70,000 | 1,533,000 | 70,000 | |
Apr 19 2017 | AXON | Axovant Sciences L ... | FALBERG KATHRYN E | Director | Buy | P | 18.54 | 53,937 | 999,992 | 53,937 | 0 to 53.9 K |
Mar 03 2017 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | P | 43.38 | 20,000 | 867,664 | 60,000 | 40 K to 60 K (+50.00 %) |
Nov 16 2016 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | P | 25.99 | 40,000 | 1,039,600 | 40,000 | 0 to 40 K |
Nov 16 2016 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | P | 25.49 | 20,000 | 509,800 | 40,000 | 20 K to 40 K (+100.00 %) |
Nov 16 2016 | TTD | Trade Desk, Inc. | FALBERG KATHRYN E | Director | Buy | P | 25.92 | 20,000 | 518,400 | 20,000 | 0 to 20 K |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | D | 58.89 | 6,228 | 366,767 | 0 | |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | D | 55.45 | 6,284 | 348,448 | 0 | |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | D | 38.89 | 9,584 | 372,686 | 0 | |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | D | 24.60 | 12,232 | 300,907 | 0 | |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | D | 27.18 | 30,000 | 815,400 | 0 | |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Sell | U | 0.00 | 50,000 | 0 | 0 | 50 K to 0 (-100.00 %) |
Sep 30 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Sell | U | 0.00 | 32,742 | 0 | 0 | 32.7 K to 0 (-100.00 %) |
Jul 19 2016 | BMRN | BIOMARIN PHARMACEU ... | FALBERG KATHRYN E | Director | Option Exercise | A | 92.08 | 8,230 | 757,818 | 8,230 | |
Jul 19 2016 | BMRN | BIOMARIN PHARMACEU ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 3,300 | 0 | 3,300 | 0 to 3.3 K |
Jun 23 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | A | 58.89 | 6,228 | 366,767 | 6,228 | |
Jun 23 2016 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 2,972 | 0 | 32,742 | 29.8 K to 32.7 K (+9.98 %) |
May 27 2016 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Option Exercise | A | 15.40 | 19,755 | 304,227 | 19,755 | |
May 26 2016 | LIFE | aTYR PHARMA INC | FALBERG KATHRYN E | Director | Option Exercise | A | 3.33 | 18,000 | 59,940 | 18,000 | |
May 06 2016 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,202 | 0 | 358,253 | 338.1 K to 358.3 K (+5.98 %) |
Jan 29 2016 | LIFE | aTYR PHARMA INC | FALBERG KATHRYN E | Director | Option Exercise | A | 6.14 | 19,428 | 119,288 | 19,428 | |
Jan 14 2016 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Option Exercise | M | 4.94 | 10,000 | 49,400 | 0 | |
Jan 14 2016 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Option Exercise | M | 10.37 | 10,000 | 103,700 | 0 | |
Jan 14 2016 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Buy | M | 4.94 | 10,000 | 49,400 | 338,051 | 328.1 K to 338.1 K (+3.05 %) |
Jan 14 2016 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Buy | M | 10.37 | 10,000 | 103,700 | 328,051 | 318.1 K to 328.1 K (+3.14 %) |
Aug 11 2015 | AIMT | Aimmune Therapeuti ... | FALBERG KATHRYN E | Director | Buy | P | 16.00 | 25,000 | 400,000 | 94,894 | 69.9 K to 94.9 K (+35.77 %) |
Jul 10 2015 | LIFE | aTYR PHARMA INC | FALBERG KATHRYN E | Director | Option Exercise | A | 14.96 | 6,286 | 94,039 | 6,286 | |
Jun 18 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Option Exercise | A | 110.90 | 3,142 | 348,448 | 3,142 | |
Jun 18 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 1,578 | 0 | 14,885 | 13.3 K to 14.9 K (+11.86 %) |
May 07 2015 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 13,175 | 0 | 318,051 | 304.9 K to 318.1 K (+4.32 %) |
Mar 02 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Buy | P | 119.11 | 800 | 95,288 | 25,000 | 24.2 K to 25 K (+3.31 %) |
Mar 02 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Buy | P | 118.37 | 1,400 | 165,718 | 24,200 | 22.8 K to 24.2 K (+6.14 %) |
Mar 02 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Buy | P | 117.76 | 19,400 | 2,284,544 | 22,800 | 3.4 K to 22.8 K (+570.59 %) |
Mar 02 2015 | MDVN | MEDIVATION, INC. | FALBERG KATHRYN E | Director | Buy | P | 116.51 | 3,400 | 396,134 | 3,400 | 0 to 3.4 K |
May 31 2005 | HGSI | HUMAN GENOME SCIEN ... | FALBERG KATHRYN E | Director | Option Exercise | A | 11.51 | 16,000 | 184,160 | 16,000 | |
Mar 04 2004 | HGSI | HUMAN GENOME SCIEN ... | FALBERG KATHRYN E | Director | Option Exercise | A | 12.93 | 48,000 | 620,640 | 48,000 |
Page: 1